The aim of this study was to determinate the serum levels of malondialdehyde (MDA) in patients with invasive breast cancer in relation to its serum levels in patients with benign disease, and to investigate correlation between MDA serum levels with pathohistological prognostic factors (tumor size, lymphe node involvement, and histological grade [HG]), estrogen receptor (ER) status, and with breast cancer patient's age and menopausal status. A total of 43 with well-documented invasive breast cancer were included in this study: 27 with positive axillary's lymph nodes, and 39 patients with findings of benign breast disease. MDA determination in serum of breast cancer disease and benign breast disease patients was performed by fluorimetric method, immunohistochemical staining was performed for ER, and routine pathohistological examination was conducted for pathohistological factors. MDA serum levels in breast cancer patients were significantly higher than MDA serum levels in benign breast disease patients (p = 0,042). No statistically significant difference between MDA serum levels in breast cancer patients with and without lymph node metastases was found (p = 0,238). No statistically significant correlations between MDA serum levels and tumor size (p = 0,256), HG (p = 0,124), or number of positive lymph nodes (p = 0,113) were found. A statistically significant correlation between serum MDA levels nad ages of breast cancer patients with lymph node metastases was found (p = 0,006). Obtained results support the importance of MDA in carcinogenesis of breast cancer. According to our findings, serum level of MDA could not be a useful prognostic factor in breast cancer.

Dr.Jasmina Gradascevic-Gubaljevic is working as a Associate Professor of Biochemistry in European University Kallos at Lecturing and experimental practice with students of Medicine Faculty and Faculty of Health Sciencies. she completed Doctoral dissertation during 2017 and also she completed Master labour during 2012.Her research focuses on breast cancer, benign breast disease, oxidative stress, malondialdehyde, pathohistological factors, and oestrogen receptors, and she has attended several conferences and published a book.